Substance Abuse Program (SAP)

Mission:

To protect the citizens of the Commonwealth and to provide a safe, secure and humane environment for staff and offenders in carrying out the mandates of the legislative and judicial processes; and, to provide opportunities for offenders to acquire skills which facilitate non-criminal behavior.

 SAP - An Overview

The Division of Substance Abuse Services is responsible for the clinical and administrative oversight of all substance abuse treatment related to inmates, parolees and probationers within our care as determined by statute. This oversight includes treatment in prisons, jails, halfway houses, Recovery Kentucky Centers, and Intensive Outpatient Programs through a partnership with regional Community Mental Health Centers as well as substance abuse clinical determination for probationers and parolees through a network of social service clinicians in the Probation & Parole districts. To date, the department has programs in the following:

  • IO programs in 7 prisons
  • 26 programs in 23, jails
  • 11 halfway house programs
  • 13 Recovery Kentucky Centers
  • 14 Intensive Outpatient Programs-Community Mental Health Centers
  • 3 Regional Intensive Outpatient Programs (Louisville, Lexington, Northern Kentucky)
  • 36 Social Service Clinicians assigned to Probation & Parole Districts

The department has expanded programming from 475 treatment beds in 2004, to a current level of 5,901 treatment slots. This is an overall growth of over 1,300%. We continue to monitor for the necessity of additional programs. All prison and jail programs are licensed through the Office of Inspector General.

In 2015, the General Assembly allocated $10 million to the Justice and Public Safety Cabinet under SB 192. Of that, $3 million was for the Department of Corrections to fund Medically Assisted Treatment (MAT) in jails and prisons. In March of 2016, the Division of Substance Abuse Services was one f the first prison jurisdictions in the nation to initiate a protocol for MAT, utilization of injectable Naltrexone (Vivitrol) to inmates who meet the criteria for high risk opiate and/or heroin use. Our protocol and implementation has resulted in our designation as a Center of Innovation by the Bureau of Justice.

Please enter your mobile content below

Note: All content entered within the mobile content area will only show up on your mobile site, and will in no way display on your desktop-ready website.

All content should be mobile-ready. Find mobile formatting rules at Sharepoint Help.